THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN OXFORD BIOMEDICA PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF OXFORD BIOMEDICA PLC.

16 February 2022

Oxford Biomedica plc ("Oxford Biomedica" or the "Company")

Publication of Circular and Notice of General Meeting

Further to the announcements on 28 January 2022 in relation to the Firm Placing and the Conditional Placing to raise approximately £80 million, Oxford Biomedica confirms that a circular in relation to the Conditional Placing (including the Retail Offer) and a related party transaction in connection with the Conditional Placing (the "Circular") has been approved by the Financial Conduct Authority (the "FCA"). The Circular contains a notice convening the General Meeting (the "Notice of General Meeting"), which is to be held at Windrush Court, Transport Way, Oxford, OX4 6LT on 8 March 2022 at 13:00 at which three resolutions will be proposed to approve the issue of 648,016 Conditional Placing Shares to Novo Holdings (as a related party), to authorise the allotment of 5,018,134 Conditional Placing Shares and to dis-apply statutory pre-emption rights otherwise applicable to the allotment of the Conditional Placing Shares.

The Circular will shortly be submitted to the FCA's National Storage Mechanism and will be available for inspection on its website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The Circular (including the Notice of General Meeting) will be posted today to shareholders who have elected to receive hard copy documents. The Circular (including the Notice of General Meeting) will also be available for viewing on Oxford Biomedica's website at www.oxb.com.

The Company continues to expect completion of the Transaction with Homology Medicines, Inc. to occur during the week commencing 7 March 2022 and Admission of the Conditional Placing Shares to occur at 8.00 a.m. on 11 March 2022.  Any changes to this timetable will be notified by way of an announcement through a Regulatory Information Service.

Unless otherwise defined, terms used in this announcement (including in the Important Notice below) shall have the same meaning as those used in the Circular.

Enquiries

Oxford Biomedica plc                                                                                  + 44 (0) 1865 783 000 / E: ir@oxb.com

Stuart Paynter, Chief Financial Officer                                                                                                          

Sophia Bolhassan, Head of Investor Relations                                                                                                           

Peel Hunt LLP (Sponsor and Joint Bookrunner):                                     +44 (0) 20 7418 8900

James Steel

Jock Maxwell Macdonald

Sohail Akbar

WG Partners LLP (Joint Bookrunner):                                                       +44 (0) 20 3705 9330

David Wilson

Claes Spang

Satheesh Nadarajah

Consilium Strategic Communications:

Mary-Jane Elliott                                                                                               +44 (0) 7739 788 014

Matthew Neal                                                                                                    +44 (0)7720 088 468

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group. In January 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as a 20% owner. To date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com.

Important Notice

This announcement has been issued by, and is the sole responsibility of, the Company.

This announcement is restricted, and is not for publication, release or distribution, directly or indirectly, in whole or in part, in, into or from the United States, Canada, Australia, New Zealand, Japan or the Republic of South Africa or any other jurisdiction in which such publication or distribution would be unlawful.

The Conditional Placing Shares have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under the applicable securities laws of any state or other jurisdiction of the United States, Canada, Australia, New Zealand, the Republic of South Africa or Japan or of any other jurisdiction. The Conditional Placing Shares may not be offered or sold in the United States unless registered under the Securities Act or offered in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and the securities laws of any relevant state or other jurisdiction of the United States. There will be no public offering of the Conditional Placing Shares in the United States or elsewhere.

This announcement is directed only at: (A) persons in member states of the European Economic Area who are "qualified investors" within the meaning of article 2(e) of Regulation (EU) 2017/1129, (B) persons in the United Kingdom who are "qualified investors" within the meaning of Regulation (EU) 2017/1129, as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, who (i) have professional experience in matters relating to investments who fall within the definition of "investment professionals" in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or, (ii) are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2)(A) to (D) of the Order; and (C) persons to whom it may otherwise be lawfully communicated (all such persons together being referred to as "Relevant Persons"). This announcement is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The distribution of this announcement and the offering or sale of the Conditional Placing Shares in certain jurisdictions may be restricted by law. No action has been taken that would permit an offering of securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.  No prospectus or offering document has been or will be prepared in connection with the Conditional Placing. Any investment decision to buy securities in the Conditional Placing must be made solely on the basis of publicly available information. Such information is not the responsibility of and has not been independently verified by Peel Hunt LLP ("Peel Hunt") or WG Partners LLP ("WG Partners") or any of their respective affiliates.

Peel Hunt and WG Partners, which are authorised and regulated in the United Kingdom by the FCA are acting for the Company and no one else in relation to the Conditional Placing and Admission and they will not be responsible to anyone other than the Company for providing the protections afforded to customers of Peel Hunt and WG Partners or for providing advice in relation to any matter contained in this document or any matter or arrangement referred to in it. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Peel Hunt or WG Partners or any directors of the Company, or by any of their affiliates or agents, as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.